

STRATEGIC PROPOSAL DEVELOPMENT SERVICE DESIGN PORTFOLIO




ABOUT OUR ILLUSTRATION SERVICE

Expected illustration times depend on existing workloads. If you need illustration work for upcoming grant submissions, please let our team know as early as possible (at least six weeks in advance is preferred.) You can request illustration services using [our intake form](#).

Chronic Sleep Fragmentation


Nocturnal mice are prevented from sleeping during the day



Mice exposed to 2 minute intervals of sleep disruption; followed by 12 hours without interruption

Frequent Night Shifts

Artificial light sources mix up the mouse's sense of day and night, and frequent changes of schedule simulate shift work



Mice exposed to 12 hours each of one week regular light and one week inverted light

NIH R01

2024

Parasitism and Mutualism During Drought Conditions





FIGURE 1. Schematic diagram of mutualism (host-mycorrhizal) and parasitism (host-*Cuscuta*) of this proposal.

USDA NIFA

2022



PUBLICATION

2023

Major Uses of Technology Identified by Caregivers



Smartphone

Social Participation

Video calls with friends and family members



eReader

Leisure/Activity

Promote mental stimulation & relaxation through eBooks and streaming services



Digital Calendar

Instrumental Activities of Daily Living

Digital alarm reminders to take medications



Internet Access

Healthcare

Communication with providers



Smartwatch

Rest/Sleep


Track sleep patterns and raise concerns with doctor

Patient Safety

Precise location tracking and fall detection


NIA

2022




Reduces Testing Time from 24 Hours to 10-60 Minutes, Saving Money

NSF Convergence Accelerator
2023




DOD CDMRP
2023

A



B



DOE EXCHANGE
2023

CLINICAL TRIAL PLANNER

SUBGROUPS

40 SUBJECTS

GENETIC LOGIC PATTERNS

NOTIFICATIONS AND ACTIVITY AND POPK1

BACK

ABOUT

POPULATION VARIABLES

SEARCH

DESCRIPTION | DOSING | INTERACTIONS | SIDE EFFECTS

RISPERIDONE

Risperidone is an atypical antipsychotic medication, first approved for use in the USA by the Food and Drug Administration (FDA) in 1993.

[MORE...](#)

[READ MORE](#)

LITERATURE

[Trifluoperazine and Its Analog Suppressed the Tumorigenicity of Non-Small Cell Lung Cancer Cell: Applicability of Antipsychotic Drugs to Lung Cancer Treatment](#)

[Association between antipsychotic agents and risk of lung cancer: a nested case-control study](#)

[READ MORE](#)

X²AI

Pattern	Subgroup	Pvalue	Outter	Pvalue	Statistics
1	PDEK1, MAP7	0.0046	PCKA	0.0001	
2	IP116, CSK, TAP2	0.0326	BUB1, BA213	0.2324	

X²AI

TREATMENT PLANNING DASHBOARD

CASE ID

CO201

DEMOGRAPHICS

RACE White

STAGE II

AGE 54

SMOKE Yes

CHEMO Yes

NEOADJUVANT No

DIABETES Yes

:

:

BACK

ABOUT

REPURPOSED DRUG SUGGESTIONS

RIFAMPICIN | GALANTAMINE | LIPOIC ACID | VORINOSTAT

DESCRIPTION

Rifampicin is an antibiotic used to treat several types of mycobacterial infections including Mycobacterium avium complex, [MORE...](#)

INTERACTIONS

Rifampin accelerates the metabolism of several drugs, including oral anticoagulants, oral contraceptives, [MORE...](#)

[SEE MORE](#)

SUBGROUP CHARACTERISTICS

MATCHED PHENOTYPES

WHITE, STAGE II, AGE 50-60

NEOADJUVANT: NO

HYPERTENSION: YES

24 PATIENTS

PHARMACOGENIC CHARACTERISTICS

EGFR RON Met mTOR MEK Src

[EX VIVO](#) [TRIAL OUTCOMES](#) [SEE MORE](#)

NIH R01
2023